Pembrolizumab was associated with high response rates in surgically unresectable advanced desmoplastic melanoma.

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can ...

A new treatment for advanced melanoma is showing promising results for people whose tumors have stopped responding to existing therapies.

Desmoplastic melanoma, a rare subtype of melanoma, is exquisitely sensitive to anti-PD1 therapies. When making a treatment decision for a given patient, less is more.

Desmoplastic melanoma usually has a high mutation burden, and they tend to have a high response rate to anti PD-1 as monotherapy. This was the SWOG 1512 study [NCT02775851], which showed responses ...

The DecisionDx®-Melanoma test offers a precise look at a patient’s unique tumor biology, and enables patients and their care providers to co-create a personalized care plan.

Boy, 15, with advanced melanoma recalls early symptom that doctors said was a sign of puberty Samuel Gee is spreading the importance of wearing sunscreen and not tanning after being diagnosed with ...

Desmoplastic melanoma tends to present as firm, amelanotic papules. Microscopically, it reveals a proliferation of fusiform cells in the dermis and variable collagen deposition, as well as ...